As we continue into 2023, investor interest in OTC markets continues to be strong.
A key to successful investing in OTC stocks is to find companies with unusual increases in trading activity and price that may provide insight into the future potential of some of these smaller companies.
Here are four OTC stocks with big upside potential in 2023.
InnovaQor (OTC: VMCS) provides information technology solutions and services to healthcare and laboratory customers in the United States.
The company offers multiple software solutions for the medical field, including:
-M2Pro, a custom built, cloud based, electronic health record for ambulatory physician practices
-ClinLab, a turnkey client/server lab information system for mid-range laboratories
-Qira, a healthcare business analytics tool
-MedTuning which provides clinical decision support for physicians and personalized drug treatment for patients
-Advantage, a proprietary health insurance portability and accountability act compliant software to eliminate the need for paper requisitions.
The company also offers a virtual chief information officer (vCIO), IT managed services, and data analytics dashboards. In addition, it offers medical support services primarily to clinical laboratories, corporate operations, rural hospitals, physician practices, and behavioral health and substance abuse centers.
On top of the current offerings, VMCS also intends to build a communication platform designed specifically for the medical sector. The platform will facilitate communication and collaboration between peers, as well as allow for the addition of revenue-generating bolt-on offers including existing solutions and a new recruitment matching product for the healthcare sector.
VMCS is focused on monetizing its already-developed proprietary medical software, such as Electronic Health Records (EHR) and MedTuning. Sales and marketing investment could mean significant volume gains and profit from these two products
Artificial Intelligence Technology Solutions, Inc. (OTC: AITX) is a global leader in AI-driven security and productivity solutions for enterprise clients. AITX is an innovator in the delivery of artificial intelligence-based solutions that empower organizations to gain new insight, solve complex challenges, and fuel new business ideas.
Last week, the stock saw significant activity, finishing up 23.31% at $.0081 per share. This uptick in activity followed the announcement that, along with their wholly owned subsidiary, Robotic Assistance Devices, Inc., the company made an investment in Circadian Risk, Inc., a company headquartered in Ann Arbor, Michigan.
VoIP-Pal.Com, Inc. (OTC: VPLM) owns a portfolio of patents relating to Voice-over-Internet Protocol (VoIP) technology. Currently, the company is looking to monetize these patents, making this stock a rather speculative play.
Last week, the stock soared up 26.53% to $.03 per share, following the news that their patent infringement lawsuit against Amazon remains in the Western District of Texas.
The company announced that the Court of Appeals for the Federal Circuit denied Amazon’s petition for a writ of mandamus challenging the previous decision of the U.S. District Court for the Western District of Texas.
Keep VPLM on your radar, as investors seem to be very interested in this penny stock.
AAP Inc. (OTC: APPJ) is a stock that saw a large jump in activity last week, rising 65.71% to $0.0058. Investor activity piqued following an announcement detailing the company’s recent acquisition. APPJ announced the acquisition of a controlling interest in the Buddha Company, a cannabis company based in Los Angeles.
The Buddha Company is a 22,000-square-foot cannabis business located in the Arts District of downtown Los Angeles. The Buddha Company has highly desirable licenses that allow for all commercial cannabis activities at one location, including:
-Retail delivery and retail storefront
This allows the AAPJ to be fully vertically integrated and source its own products to maximize profit and minimize the tax implications of the stringent IRS rules related to the cannabis business (Section 280E).
While it seems this may be a new direction for the company, it’s impossible to ignore the interest that investors have taken in APPJ.
Disclaimers: This article contains sponsored content.The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. Capital Gains Report ‘CGR’ is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. CGR authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. CGR has been compensated to produce and syndicate content related to VMCS. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website.